

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b> 24D0406402	<b>(X3) Date Survey Completed</b> 12/14/2022
<b>Name of Provider or Supplier</b> Mahnommen Health Center	<b>Street Address, City, State</b> 414 W Jefferson Ave, Mahnommen, MN	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p><b>SUCCESSFUL PARTICIPATION</b> CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: . Based on review of proficiency testing (PT) scores from the American Proficiency Institute (API), the laboratory failed to successfully participate in PT in 2022 for human chorionic gonadotropin (HCG) under the specialty of endocrinology. Finding include: 1. The API 2022 Chemistry - Core 3rd Event Performance Summary and Comparative Evaluation were reviewed on December 14, 2022. The reports indicated the laboratory failed to achieve satisfactory performance for HCG in two consecutive testing events in 2022 resulting in unsuccessful performance. See D2107 .</p>
<b>D2107</b>	<b>ENDOCRINOLOGY</b>

CFR(s): 493.843(f)

Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

. Based on a review of proficiency testing (PT) reports from American Proficiency Institute (API), the laboratory failed to achieve satisfactory performance for human chorionic gonadotropin (HCG) in two consecutive testing events, constituting unsuccessful performance. Findings include: 1. The API 2022 Chemistry - Core 3rd Event Performance Summary and Comparative Evaluation were reviewed on December 14, 2022. Review of PT results from API indicated that the laboratory had unsatisfactory performance for HCG as follows: -Score of 60% during the 2nd event of 2022 -Score of 60% during the 3rd event of 2022 .